Last reviewed · How we verify

Allium Sativum

Suez Canal University · FDA-approved active Small molecule Quality 15/100

Allium Sativum, marketed by Suez Canal University, is positioned in the allergic symptoms segment. The key composition patent, set to expire in 2028, provides a significant competitive advantage. The primary risk is the lack of revenue data, which may affect investment and market confidence.

At a glance

Generic nameAllium Sativum
Also known asCombination of Allium Sativum and Calcium hydroxide, Calcium hydroxide
SponsorSuez Canal University
Drug classStandardized Insect Venom Allergenic Extract [EPC]
ModalitySmall molecule
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: